Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors

a technology of c5a receptors and g protein-coupled receptors, which is applied in the direction of peptide/protein ingredients, peptide sources, immunological disorders, etc., can solve the problems of enhancing inflammatory responses, lysis and cell death, and structure-function studies are extremely difficult to interpret, so as to facilitate the assembly of a “membrane attack complex, avoid stepwise amplification of proteolysis, and promote inflammation

Inactive Publication Date: 2006-07-20
PROMICS
View PDF4 Cites 46 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0003] During host defence, the complement system of plasma proteins initiates inflammatory and cellular immune responses to stimuli such as infectious organisms (bacteria, viruses, Parasites), chemical or physical injury, radiation or neoplasia. Complement is activated through a complex cascade of interrelated proteolytic events that produce multiple bioactive peptides, some of which (eg. anaphylatoxins C3a and C5a) interact with cellular components to propagate inflammatory processes. Complement activation, either by the classical pathway, after antigen-antibody (Ag/Ab) binding, or by the antibo

Problems solved by technology

The latter facilitates assembly of a “membrane attack complex” that punches holes in membranes of target cells such as bacteria, leading to leakage, lysis and cell death.
If these regulatory mechanisms become inefficient, protracted activation of complement can result, causing e

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
  • Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
  • Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Structure-Activity Relationship of C5a Agonists

[0103] We have focussed on the C-terminal residues of C5a, in order to explore structure-activity relationships in the search for peptide sequences with potent agonists activity. Many of these peptides are full agonists relative to C5a, but have markedly lower potency (Sanderson et al, 1994, 1995; Finch et al, 1997) Our initial structure-activity investigations have been particularly informative. Mutating the decapeptide C-terminus of C5a (1, C5a65-74, ISHKDMQLGR) twice I65Y and H67F (eg. 2) led to enhancement of agonist potency by about 2 orders of magnitude. These results are summarised in Table 2. Analyses of Ramachandran plots and 2D NMR spectra for compound 2 suggested that certain structural features, namely a twisted “helix-like” backbone conformation for residues 65-69 and a β-turn for residues 71-74, might be responsible for activity. These preliminary results provided some insight to structural requirements for tight binding ...

example 2

NMR Structure of C5a Antagonist

[0107] We used two dimensional nuclear magnetic resonance spectroscopy to determine the three dimensional structure of 7 and found that while there is no discernible structure in water, there is evidence of a stable gamma-turn structure in dimethylsulfoxide.

[0108] The 1D 1H-NMR spectrum of peptide 7 in d6-DMSO at 24° C. shows 4 distinct resonances for amide-NH protons, as summarized in Table 3. To establish their possible involvement in intramolecular hydrogen bonds, a deuterium exchange experiment was performed by adding a 10-old excess of D2O to the solution. Two of the amide-NH doublets disappeared immediately, along with resonances attributable to the N-terminal methylamine protons. However, the other two amide NH resonances, as well as a broad resonance at approximately 8.05 ppm, persisted for up to 6.5 hours (FIG. 2). These three slowly-exchanging protons are assigned to the amide NHs of Trp and d-Cha and the side chi amine of Lys, the slow exc...

example 3

Structure-Activity Relationships In Vitro

[0114] We also examined the receptor-binding and antagonist activity of the hexapeptide 7 for comparison with our new compounds. The previous report by Konteatis et al (1994) concerned the ability of 7 to compete with C5a binding to receptors on isolated PMN membranes (IC50 70 nM), which is not necessarily physiologically relevant. We examined competition between 7 and C5a using intact PMN cells, and found that, under these conditions, 7 binds with much lower receptor affinity of IC50 1.8 μM. We confirmed that 7 is a full antagonist with no agonist properties. These results are summarized in FIG. 5a and Table 4. The relative affinity (ratio) of 7 for the C5aR in intact PMNs in our assays was similar to that previously reported for isolated PMN membranes.

[0115] We have also found that 7 shows antagonist activity against both C5a (FIG. 5b) and a C-terminal agonist decapeptide analogue 4 (YSFKPMPLaR) (Finch et al, 1997) of the C-terminus C5a65...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Structureaaaaaaaaaa
Login to view more

Abstract

The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.

Description

[0001] This invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The invention provides both agonists and antagonists. In preferred embodiments, the invention provides cyclic peptidic and cyclic or non-cyclic non-peptidic antagonists or agonists of C5a. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions. BACKGROUND OF THE INVENTION [0002] Activation of human complement, a system of plasma proteins involved in immunological defence against infection and injury, contributes significantly to the pathogenesis of numerous acute and chronic diseases. In particular, the complement protein C5a has been extensively investigated. For general reviews, see Whaley (1987), and Sim (1993). Table 1 provides a summary of known roles of C5a in disease. [0003] During host defence, the complement system of plasma proteins initiates inflammatory and ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/12C07K5/12A61K38/00A61K38/08A61P1/02A61P9/10A61P11/00A61P17/06A61P19/02A61P25/28A61P29/00A61P37/06C07K7/00C07K7/06C07K7/56C07K7/64C07K14/47
CPCA61K38/00C07K7/56C07K14/472C07K2299/00A61P1/02A61P11/00A61P17/06A61P19/02A61P25/00A61P25/28A61P29/00A61P37/06A61P9/10
Inventor FAIRLIE, DAVIDTAYLOR, STEPHENFINCH, ANGELAWONG, ALLAN
Owner PROMICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap